TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma

Autor: Tianzhu Qiu, Xiaoxuan Wang, Furong Du, Xiangjing Hu, Fujun Sun, Chao Song, Jie Zhao
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: World Journal of Surgical Oncology, Vol 20, Iss 1, Pp 1-11 (2022)
Druh dokumentu: article
ISSN: 1477-7819
DOI: 10.1186/s12957-022-02581-7
Popis: Abstract Background The ten-eleven translocation 1 (TET1), which is essential for active DNA demethylation, plays a multifaceted role in the pathogenesis of colorectal cancer. The study has demonstrated the association of TET1 mutations with a high response to immune checkpoint inhibitors (ICIs) in diverse cancers. However, the relationship between TET1 mutations and the response to ICIs in colon cancer is still lacking. Methods The prognosis, predictive markers, immune characteristics, mutation number of DNA damage repair (DDR) pathways, pathway enrichment, and drug sensitivity conditions were all compared between TET1-mutated and wild-type patients with colon adenocarcinoma (COAD). Results The overall survival of patients with TET1 mutations in the ICI-treated cohort was significantly longer than those without (p = 0.0059). Compared with the wild-type patients, TET1-mutated patients had higher tumor mutational burden and neoantigen load, enhanced abundance of tumor-infiltrating immune cells, increased expression of immune-related genes, and mutation number of DDR pathways. Additionally, the patients with TET1 mutations were found to be more sensitive to lapatinib and 5-fluorouracil. Conclusion These findings suggest that TET1 mutations may serve as a potential biomarker for the response to ICIs in COAD patients.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje